RT期刊文章SR电子T1职业sthma due to ceftazidime JF European Respiratory Journal JO Eur Respir J FD European Respiratory Society SP 1421 OP 1423 VO 8 IS 8 A1 Stenton, SC A1 Dennis, JH A1 Hendrick, DJ YR 1995 UL //www.qdcxjkg.com/content/8/8/1421.abstract AB A worker employed in the manufacture of the new third generation cephalosporin antibiotic, ceftazidime, developed asthmatic symptoms, and a series of inhalation challenge tests was undertaken to investigate the problem. The inhalation of increasing daily doses of ceftazidime up to 3.2 mg, using a double-blind challenge protocol gave rise to symptoms, late asthmatic reactions, and increases in airway responsiveness to methacholine. A repeat challenge with the 3.2 mg dose additionally gave rise to a clear immediate reaction. Ceftazidime was, thus, shown to be capable of inducing occupational asthma.